Opexa Therapeutics Reports Second Quarter 2013 Financial Results and Provides Corporate Update

Published: Aug 14, 2013

Regeneron may be hiring! Check it out! (Isn't it tempting?)

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2013 and provided an overview of recent corporate developments.

Help employers find you! Check out all the jobs and post your resume.

Back to news